GHK-Cu Copper Peptide: What the Research Shows

GHK-Cu is a copper-binding tripeptide, glycine–histidine–lysine, that occurs naturally in human plasma. Since it was first identified in 1973 it has become one of the most-studied peptides in skin and tissue-remodelling research, mostly in cell cultures and animal models, with a smaller body of topical human data.

This guide covers what GHK-Cu is, what the published studies actually measured, where the evidence stops, and what to check when sourcing research-grade GHK-Cu in Canada.

What GHK-Cu is

GHK is a three-amino-acid peptide made of glycine, histidine and lysine. It binds copper(II) ions tightly, and the resulting complex, GHK-Cu, is the form most research uses. The copper is also why the powder and its solutions are blue; plain GHK is white.

The same Gly-His-Lys sequence sits inside the α2(I) chain of type I collagen. Researchers have proposed that enzymes breaking down collagen at a wound could release GHK locally, which would make it a natural local repair signal. That idea comes from the 1988 fibroblast study described below and remains a hypothesis.

GHK circulates in human plasma, and its concentration falls with age. That decline is a large part of why GHK-Cu draws attention in ageing research.

A short research history

1. 1973Loren Pickart identifies GHK as an activity in human plasma albumin that made aged liver tissue synthesize proteins more like younger tissue.
2. 1988Maquart and colleagues report that GHK-Cu stimulates collagen synthesis in fibroblast cultures, starting at picomolar concentrations and peaking near 1 nanomolar.
3. 1992The same group shows GHK-Cu increases glycosaminoglycan synthesis by human fibroblasts.
4. 1993In rat wound chambers, GHK-Cu increases collagen, glycosaminoglycans, DNA and total protein in a concentration-dependent way.
5. 2000GHK-Cu is found to raise MMP-2 together with its inhibitors TIMP-1 and TIMP-2, pointing to remodelling rather than simple build-up.
6. 2012A lung gene-expression study with co-authors at the University of British Columbia identifies GHK as a compound that reverses an emphysema-associated gene signature.
7. 2018Pickart and Margolina review the accumulated gene data and propose GHK as a broad regulator of repair-related pathways.

What the studies measured

Collagen and the extracellular matrix

Most of the foundational GHK-Cu work used cultured dermal fibroblasts, the cells that build the skin’s structural matrix. In those cultures GHK-Cu increased collagen synthesis without changing cell number, and increased glycosaminoglycans such as dermatan sulfate and heparan sulfate. Later work showed it also raised matrix metalloproteinase-2 alongside the enzyme’s inhibitors, which researchers read as balanced remodelling: building new matrix while clearing old.

Wound models in animals

The clearest in-vivo data come from rat wound-chamber experiments, where GHK-Cu placed into implanted chambers increased connective-tissue accumulation. A control tripeptide had no significant effect, which suggests the response depends on the GHK sequence rather than on peptide content in general. Further reading: Angiogenesis and VEGF Explained: How New Blood Vessels Form.

Gene expression

Since about 2010, GHK research has shifted toward gene-expression data. The Connectivity Map is a public database that records how thousands of compounds change gene activity in cultured human cells. When researchers compared a gene signature of emphysema lung damage against that database, GHK stood out as a compound that pushed expression in the opposite direction. Treating lung fibroblasts with GHK then reorganized their actin cytoskeleton and raised integrin β1 expression.

These results are interesting because they are broad, but they come from cell lines and database correlations. They identify questions worth testing; they don’t show what GHK-Cu does in a living organism.

Topical cosmetic research

GHK-Cu is widely used in skin and hair-care formulations, and that market has produced small human studies of topical creams. Those studies are generally short and small, and cosmetic use is a different question from laboratory research with a purified reagent.

Where the evidence stops

• No large controlled trials. There are no large randomized trials of GHK-Cu beyond small cosmetic studies, and none of systemic use.
• Concentration matters. Many effects appeared at nanomolar concentrations in culture dishes, which doesn’t translate directly to a whole organism.
• Replication. Much of the review literature comes from a small number of research groups, including authors affiliated with a skin-care research company. Independent replication is still the missing piece.
• Database matches are hypotheses. The Connectivity Map finds compounds whose gene effects run opposite to a disease signature. It’s a screening tool, not proof of a treatment effect.

Copper peptides: the wider family

“Copper peptides” is the everyday name for short peptides that carry a bound copper(II) ion. In practice the term almost always means GHK-Cu, which has by far the largest research literature, but it also covers close relatives such as AHK-Cu. In both, the copper is held by the histidine side chain together with nearby backbone nitrogen atoms, which is why swapping the first amino acid keeps the copper-binding behaviour.

AHK-Cu and hair follicles

The AHK-Cu literature rests mainly on one 2007 study by a Korean dermatology group. At picomolar to nanomolar concentrations, AHK-Cu lengthened isolated human hair follicles kept alive in culture and increased the proliferation of dermal papilla cells, the specialized cells that drive follicle growth. It also shifted markers of programmed cell death in a protective direction, although the fall in apoptotic cells itself was not statistically significant. No human trials of AHK-Cu have been published.

Copper peptides in skincare

Most people meet copper peptides in skin and hair-care products, where GHK-Cu has been used for decades. Those formulations have produced small human studies of topical creams, which answer a different question from laboratory work with a purified reagent: concentration, vehicle and skin penetration all change the result. For the other main family of cosmetic peptides, see our guide to Argireline and SNAP-8.

GHK-Cu, AHK-Cu and blends

AHK-Cu swaps the first amino acid, alanine in place of glycine, giving a closely related copper tripeptide that is mostly discussed in hair-follicle research. If your work is specifically about GHK, check that the label and COA say GHK-Cu, since the two are easy to confuse. AHK-Cu is listed separately in our catalogue.

Blends combine GHK-Cu with other repair-research peptides in one vial. They’re useful when a study design calls for the combination and less useful when you need to isolate one compound’s effect. Our KLOW blend explainer walks through the four-peptide version.

GHK-CuThe copper tripeptide on its own, for single-compound work.View product and COA GHK-Cu + KPVThe copper peptide paired with the KPV tripeptide.View product and COA Glow blendGHK-Cu combined with BPC-157 and TB-500.View product and COA Klow blendGlow’s three peptides plus KPV in one vial.View product and COA

Sourcing GHK-Cu in Canada

Pure Peptides Canada is a Canadian-owned supplier of laboratory research peptides, established in 2023. Whoever you buy from, GHK-Cu quality varies between suppliers, so check these points before ordering:

• A batch-specific COA. The lot number on the certificate should match the lot on your vial. Our COA guide shows what to look for.
• Purity and identity testing. HPLC measures purity; mass spectrometry confirms the molecule is what the label says. Here’s how the two tests differ.
• The right colour. GHK-Cu should be blue to violet. A white powder sold as GHK-Cu suggests the copper is missing.
• Cold, dry storage. Lyophilized peptides keep best cold, dry and dark. See our peptide storage guide.
• Tracked delivery with a clear timeline. Long international transits add customs holds and temperature swings.

Regulatory status in 2026

GHK-Cu sits in two regulatory worlds. As a topical ingredient it is widely used in skin and hair-care formulations. As an injectable peptide it is unauthorized: Health Canada’s April 2026 advisory on unauthorized injectable peptides listed GHK-Cu among products it had seized, and stated that “For Research Use Only” labelling does not make such products legal or exempt from regulatory requirements.

In the United States, the FDA placed GHK-Cu for injectable use in Category 2 of its compounding list, the group of substances that raise significant safety risks, in 2023. In 2026 it removed injectable GHK-Cu from that category and said it would consult its Pharmacy Compounding Advisory Committee at a meeting expected before February 2027. Removal from Category 2 does not by itself make it eligible for US compounding, and injectable GHK-Cu is not an FDA-approved drug.

Frequently asked questions

Prepared by Pure Peptides Canada. Sources checked October 2026. For laboratory research use only; not for human or veterinary use. This article summarizes published research for education and is not medical advice. Nothing here is intended to diagnose, treat, cure or prevent any disease.